If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

4 Nov 2014 07:00

RNS Number : 0309W
Biome Technologies PLC
04 November 2014
 



04 November 2014

 

 

Biome Technologies plc ("Biome", "the Company" or "the Group")

Trading Update

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes a trading update for the nine months ended 30 September 2014.

 

Total Group revenues achieved for the third quarter were £0.5m (Q3 2013: £0.6m) taking Group revenues for the nine months to 30 September 2014 to £2.8m, 85% ahead of the same period in 2013 (2013: £1.5m). The Group's cash position as at 30 September 2014 was £2.8m (30 June 2014: £3.1m).

Bioplastics Division

Revenues for the Bioplastics division in Q3 were £0.1m (Q3 2013: £0.4m), down substantially on the previous two quarters. Offtake reduced to the single-serve coffee market in the USA as the main customer responded to technical challenges in the market place and ran down stocks ahead of re-launches. The Board believes that these effects are temporary and that revenue growth will resume in the near future.

Further progress was made in the development of the pipeline of new bioplastic polymers with technical and customer trials continuing in both the food service and paper-board coating sectors. The business launched a new product in September, formulated to improve both speed and performance in 3D printing applications, whilst retaining impeccable environmental credentials. This is the division's first foray into this emerging sector and initial response from end-use customers is encouraging.

Earlier in the year, the division announced the successful completion of a feasibility study undertaken in conjunction with the University of Warwick and supported by Innovate UK (formerly the Technology Strategy Board). This study examined the feasibility of producing a bacterially derived lignin-based alternative to the oil-based chemicals used in the manufacture of bioplastics. The Board is exploring options for further scale-up of this technology and is awaiting the result of a further grant application to Innovate UK. The result of this application is expected in the near future.

 

Stanelco RF Technologies Division

Revenues for the RF division remained firm at £0.4m (Q3 2013: £0.2m). Demand from the optical fibre furnace market in Asia continues to underpin revenues whilst products for a broader portfolio of market applications are progressing well. The unit's order-book into 2015 is robust and recruitment has been recently completed to extend both capacity and capability.

 

Outlook

The Board remains confident of meeting market expectations for the year.

 

-Ends-

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

Daniel Stewart & Company plc

Paul Shackleton (Nominated Adviser)

Mark Treharne (Broker)

www.danielstewart.co.uk

Tel: +44 (0) 20 7776 6550

Allenby Capital

Chris Crawford/Kelly Gardiner

www.allenbycapital.com

Tel: +44 (0) 20 3002 2070

FTI Consulting

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQKNDBABDDPDK
Date   Source Headline
29th Jan 20157:00 amRNSOperational Update
22nd Jan 20157:00 amRNSPre-close Trading Statement
21st Jan 20154:35 pmRNSHolding(s) in Company
11th Dec 201410:11 amRNSChange of Adviser
14th Nov 20149:58 amRNSHolding(s) in Company
4th Nov 20147:00 amRNSTrading Update
3rd Sep 20147:00 amRNSInterim Results
12th Aug 20149:36 amRNSHolding(s) in Company
31st Jul 20147:00 amRNSContract progress for RF Technologies Business
24th Jul 20143:28 pmRNSTrading Update
6th Jun 20143:56 pmRNSHolding(s) in Company
7th May 20147:00 amRNSEMI Share Option Plan
23rd Apr 201412:26 pmRNSResult of AGM and Appointment of Director
23rd Apr 20147:00 amRNSTrading Update
31st Mar 20147:00 amRNSUpdated Corporate Presentation
28th Mar 20147:02 amRNSPosting of Notice of AGM & Annual Report
27th Mar 20147:00 amRNSPreliminary Results
24th Mar 201411:43 amRNSContract for Stanelco RF Technologies Division
19th Feb 20149:01 amRNSHolding(s) in Company
24th Jan 20147:00 amRNSPre-close Trading Statement
4th Dec 20133:37 pmRNSIssue of Shares to Director
28th Nov 20131:30 pmRNSDirector/PDMR Shareholding
27th Nov 20137:00 amRNSHolding(s) in Company
4th Nov 20137:00 amRNSTrading Update
31st Oct 201312:27 pmRNSTotal Voting Rights
2nd Oct 201312:47 pmRNSIssue of Shares to a Director
27th Sep 20138:51 amRNSTR-1: Notification of Major Interest in Shares
25th Sep 201312:33 pmRNSResult of General Meeting
2nd Sep 20137:10 amRNSNotice of General Meeting
2nd Sep 20137:00 amRNSInterim Results
26th Jul 20137:00 amRNSPurchase of Shares following Consolidation
18th Jul 20137:00 amRNSInterim Management Statement
20th Jun 20132:34 pmRNSIssue of Equity
20th Jun 201312:45 pmRNSResult of General Meeting
17th Jun 201312:01 pmRNSHolding(s) in Company
17th Jun 201311:59 amRNSHolding(s) in Company
23rd May 20137:01 amRNSCapital Reorganisation
23rd May 20137:00 amRNSSettlement with Landlord in Respect of Leases
26th Apr 20137:00 amRNSIssue of shares to a Director Total Voting rights
25th Apr 20134:10 pmRNSResult of AGM
25th Apr 20137:00 amRNSTrading Update
4th Apr 20137:00 amRNSResearch Grant Award
3rd Apr 20134:35 pmRNSNotice of AGM and Annual Report and Accounts
28th Mar 20137:10 amRNSDirector's Remuneration and Consultancy agreement
28th Mar 20137:01 amRNSPreliminary Results
23rd Jan 20137:00 amRNSPre-close Trading Statement
2nd Nov 20127:00 amRNSTrading Update
1st Oct 20123:24 pmRNSCompletion of Sale
27th Sep 20122:03 pmRNSResult of General Meeting
7th Sep 20127:00 amRNSProposed Sale of stake in Biotec Holding GmbH

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.